Adalimumab therapy for refractory uveitis: results of a multicentre, open-label, prospective trial
Adalimumab therapy for refractory uveitis: results of a multicentre, open-label, prospective trial
About this item
Full title
Author / Creator
Publisher
BMA House, Tavistock Square, London, WC1H 9JR: BMJ Publishing Group Ltd
Journal title
Language
English
Formats
Publication information
Publisher
BMA House, Tavistock Square, London, WC1H 9JR: BMJ Publishing Group Ltd
Subjects
More information
Scope and Contents
Contents
Objective Tumour necrosis factor (TNF) blockers have been demonstrated to be effective in the treatment of systemic and ocular inflammatory diseases. We conducted a prospective, multicentre, open-label Phase II clinical trial to assess the effectiveness and safety of adalimumab, a fully human anti-TNF monoclonal antibody, in treating refractory uve...
Alternative Titles
Full title
Adalimumab therapy for refractory uveitis: results of a multicentre, open-label, prospective trial
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_1778951192
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_1778951192
Other Identifiers
ISSN
0007-1161
E-ISSN
1468-2079
DOI
10.1136/bjophthalmol-2012-302292
